Roche's (RHHBY) Lymphoma Drug Polivy Gets Approval In Europe
Zacks Investment Research | Jan 21, 2020 06:13AM ET
Roche (OTC:RHHBY) announced that the European Commission (EC) granted conditional marketing authorization to oncology drug, Polivy.
Polivy is a first-in-class anti-CD79b antibody-drug conjugate (ADC).
The EC approved Polivy (polatuzumab vedotin) in combination with bendamustine plus MabThera (rituximab) (BR) for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not candidates for a hematopoietic stem cell transplant.
The conditional approval is based on the results from the phase Ib/II GO29365 study. The study data showed that 40% of people treated with Polivy plus BR achieved a complete response compared to 17.5% with BR alone.
Conditional approval is granted to drugs that fulfill unmet medical needs, where the benefit of immediate availability outweighs the risk of less comprehensive data than normally required.
In June 2019, the drug in combination with BR was also granted accelerated approval by the FDA for the treatment of patients with R/R DLBCL, who have received at least two prior therapies. The drug was granted Breakthrough Therapy designation by the FDA and PRIME (PRIority MEdicines) designation by the European Medicines Agency (EMA) for the treatment of people with R/R DLBCL in 2017.
Polivy was developed by Roche using Seattle Genetics’ (NASDAQ:SGEN) ADC technology and is currently being investigated for the treatment of non-Hodgkin lymphoma (NHL).
The stock has gained 31.7% in the past year compared with the industry 's 15.1% growth.
The approval of Polivy will strengthen Roche’s hematology portfolio, which comprises approved drugs like MabThera/Rituxan, Tecentriq, Gazyva and Venclexta, in collaboration with AbbVie (NYSE:ABBV) . The company also has Hemlibra in its portfolio for the treatment of hemophilia A.
Roche is currently looking to diversify its portfolio in wake of stiff competition from biosimilars for key drugs such as Avastin, Rituxan and Herceptin from Novartis and Amgen (NASDAQ:AMGN) .
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Get The News You Want
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.